– Acquisition extends Glooko’s diabetes digital well being platform into hospitals, making a complete inpatient-to-outpatient diabetes administration linked care resolution –
– Deal underscores Glooko’s dedication to accelerating development and innovation in diabetes care –
PALO ALTO, Calif.–(BUSINESS WIRE)–Glooko, Inc., a number one supplier of distant affected person monitoring and digital well being options for diabetes, at the moment introduced that it has acquired Monarch Medical Applied sciences, the developer of the EndoTool® Glucose Administration System. EndoTool is an industry-leading software program platform for inpatient insulin dosing and glycemic administration. This strategic acquisition expands Glooko’s linked care capabilities into inpatient glycemic administration, complementing its robust basis in outpatient diabetes administration and shaping the way forward for a single, built-in resolution that may help sufferers and clinicians throughout the complete continuum of care.
“This acquisition represents a pivotal step in Glooko’s mission to remodel diabetes administration in each care setting,” mentioned Mike Alvarez, Chief Govt Officer of Glooko. “We’ve constructed a robust basis within the outpatient area — simplifying diabetes administration for clinicians by way of unified machine integration, EHR connectivity, and actionable insights. By including Monarch’s confirmed inpatient insulin dosing experience, we’re now uniquely positioned to ship a really complete hospital-to-home resolution that may enhance outcomes, streamline workflows, and improve affected person security. Trying forward, this platform additionally creates alternatives to increase our management into major care and superior glycemic administration, enabling us to serve sufferers and suppliers throughout the complete continuum of care.”
Inpatient glycemic administration is important to affected person security, outcomes, and hospital efficiency, with 30–40% of hospitalized sufferers requiring insulin remedy to take care of acceptable glucose management.1 Poor glucose administration can result in severe issues, longer stays, and better prices. EndoTool, an FDA-cleared software program platform that assists clinicians in optimizing insulin dosing for hospitalized sufferers, makes use of a patented, patient-specific algorithm to ship exact, guideline-aligned insulin dosing in actual time, lowering the chance of hypoglycemia and serving to hospitals meet CMS high quality measures whereas streamlining medical workflows.
“Efficient glycemic administration doesn’t start or finish on the hospital doorways. It’s a steady journey,” mentioned Mark Clements, M.D., Ph.D., Chief Medical and Technique Officer at Glooko. “With new CMS high quality measures and HEDIS metrics driving the necessity for constant glucose management, linked options are now not elective, they’re important. By integrating EndoTool with Glooko’s outpatient platform, we imagine we might be higher in a position to make sure safer care transitions for folks with diabetes, assist hospitals meet high quality and regulatory necessities, and ship measurable enhancements in affected person outcomes throughout the continuum.”
The acquisition of Monarch Medical advances Glooko’s strategic concentrate on linked care in diabetes administration. Glooko’s platform, utilized by thousands and thousands of sufferers and greater than 8,000 clinics worldwide, aggregates knowledge from greater than 200 linked units – together with blood glucose meters, insulin pumps, steady glucose displays (CGMs), and others – to make diabetes administration simpler for endocrinologists, major care suppliers, nurses, diabetes educators, dietitians, and different clinicians by unifying knowledge from quite a lot of units onto a single platform, integrating easily with EHR workflows, and delivering actionable insights. By including EndoTool to its platform, Glooko will help acute care settings with precision insulin dosing algorithms, and proceed to help these sufferers post-discharge by way of its distant monitoring instruments. This built-in strategy goals to cut back hospital readmissions, improve continuity of care, and enhance total glycemic management throughout settings.
The mixed firm will preserve all present choices and help for each Glooko and EndoTool clients. Within the close to time period, Glooko and Monarch Medical will proceed to function their merchandise as they do at the moment, making certain no disruption for customers. Longterm, Glooko plans to combine each choices on a single platform.
Constructing on Robust Investor Backing
This acquisition follows Glooko’s $100 million Collection F financing spherical accomplished in October 2024, led by Georgian with participation from Canaan Companions, Well being Catalyst Capital, Mayo Ventures, Realization Capital Companions and different strategic buyers. At the moment, Glooko outlined its intent to speed up development by way of each product innovation and selective acquisitions. The addition of Monarch Medical demonstrates how that capital and investor help are fueling Glooko’s technique to develop its linked care platform, lengthen its attain into new care settings, and solidify its place as a worldwide chief in digital well being for diabetes administration.
Phrases of the acquisition should not being disclosed.
About Glooko
Glooko is targeted on bettering well being outcomes for folks with diabetes by way of our personalised, clever, linked care platform. Our confirmed applied sciences strengthen connections between sufferers and suppliers, drive affected person engagement and adherence by way of digital therapeutics, with greater than 4.4 million folks around the globe who’ve used the Glooko platform. By seamlessly integrating with digital well being information (EHRs), offering a unified machine ecosystem, and delivering actionable insights, Glooko goals to reinforce medical workflows and enhance outcomes for folks with diabetes and their care suppliers. For extra data, please go to www.glooko.com.
About Monarch Medical Applied sciences
Monarch Medical is the Charlotte, NC-based maker of the EndoTool Glucose Administration System, a number one enterprise resolution for inpatient glycemic management. Based by clinicians, Monarch’s mission is to enhance affected person security and outcomes by way of exact insulin dosing know-how. The EndoTool platform has been adopted by hospitals and well being methods throughout america to standardize and optimize insulin remedy, just about eliminating extreme hypoglycemia and lowering hyperglycemia in important care settings. For extra data, go to www.monarchmedtech.com.
1 Rushakoff RJ, Sullivan MM, MacMaster HW, et al. Affiliation between a digital glucose administration service and glycemic management in hospitalized grownup sufferers: an observational examine. Ann Intern Med 2017;166:621–627
Contacts
Media Contact
Julia Fuller
(858) 692-2001
– Acquisition extends Glooko’s diabetes digital well being platform into hospitals, making a complete inpatient-to-outpatient diabetes administration linked care resolution –
– Deal underscores Glooko’s dedication to accelerating development and innovation in diabetes care –
PALO ALTO, Calif.–(BUSINESS WIRE)–Glooko, Inc., a number one supplier of distant affected person monitoring and digital well being options for diabetes, at the moment introduced that it has acquired Monarch Medical Applied sciences, the developer of the EndoTool® Glucose Administration System. EndoTool is an industry-leading software program platform for inpatient insulin dosing and glycemic administration. This strategic acquisition expands Glooko’s linked care capabilities into inpatient glycemic administration, complementing its robust basis in outpatient diabetes administration and shaping the way forward for a single, built-in resolution that may help sufferers and clinicians throughout the complete continuum of care.
“This acquisition represents a pivotal step in Glooko’s mission to remodel diabetes administration in each care setting,” mentioned Mike Alvarez, Chief Govt Officer of Glooko. “We’ve constructed a robust basis within the outpatient area — simplifying diabetes administration for clinicians by way of unified machine integration, EHR connectivity, and actionable insights. By including Monarch’s confirmed inpatient insulin dosing experience, we’re now uniquely positioned to ship a really complete hospital-to-home resolution that may enhance outcomes, streamline workflows, and improve affected person security. Trying forward, this platform additionally creates alternatives to increase our management into major care and superior glycemic administration, enabling us to serve sufferers and suppliers throughout the complete continuum of care.”
Inpatient glycemic administration is important to affected person security, outcomes, and hospital efficiency, with 30–40% of hospitalized sufferers requiring insulin remedy to take care of acceptable glucose management.1 Poor glucose administration can result in severe issues, longer stays, and better prices. EndoTool, an FDA-cleared software program platform that assists clinicians in optimizing insulin dosing for hospitalized sufferers, makes use of a patented, patient-specific algorithm to ship exact, guideline-aligned insulin dosing in actual time, lowering the chance of hypoglycemia and serving to hospitals meet CMS high quality measures whereas streamlining medical workflows.
“Efficient glycemic administration doesn’t start or finish on the hospital doorways. It’s a steady journey,” mentioned Mark Clements, M.D., Ph.D., Chief Medical and Technique Officer at Glooko. “With new CMS high quality measures and HEDIS metrics driving the necessity for constant glucose management, linked options are now not elective, they’re important. By integrating EndoTool with Glooko’s outpatient platform, we imagine we might be higher in a position to make sure safer care transitions for folks with diabetes, assist hospitals meet high quality and regulatory necessities, and ship measurable enhancements in affected person outcomes throughout the continuum.”
The acquisition of Monarch Medical advances Glooko’s strategic concentrate on linked care in diabetes administration. Glooko’s platform, utilized by thousands and thousands of sufferers and greater than 8,000 clinics worldwide, aggregates knowledge from greater than 200 linked units – together with blood glucose meters, insulin pumps, steady glucose displays (CGMs), and others – to make diabetes administration simpler for endocrinologists, major care suppliers, nurses, diabetes educators, dietitians, and different clinicians by unifying knowledge from quite a lot of units onto a single platform, integrating easily with EHR workflows, and delivering actionable insights. By including EndoTool to its platform, Glooko will help acute care settings with precision insulin dosing algorithms, and proceed to help these sufferers post-discharge by way of its distant monitoring instruments. This built-in strategy goals to cut back hospital readmissions, improve continuity of care, and enhance total glycemic management throughout settings.
The mixed firm will preserve all present choices and help for each Glooko and EndoTool clients. Within the close to time period, Glooko and Monarch Medical will proceed to function their merchandise as they do at the moment, making certain no disruption for customers. Longterm, Glooko plans to combine each choices on a single platform.
Constructing on Robust Investor Backing
This acquisition follows Glooko’s $100 million Collection F financing spherical accomplished in October 2024, led by Georgian with participation from Canaan Companions, Well being Catalyst Capital, Mayo Ventures, Realization Capital Companions and different strategic buyers. At the moment, Glooko outlined its intent to speed up development by way of each product innovation and selective acquisitions. The addition of Monarch Medical demonstrates how that capital and investor help are fueling Glooko’s technique to develop its linked care platform, lengthen its attain into new care settings, and solidify its place as a worldwide chief in digital well being for diabetes administration.
Phrases of the acquisition should not being disclosed.
About Glooko
Glooko is targeted on bettering well being outcomes for folks with diabetes by way of our personalised, clever, linked care platform. Our confirmed applied sciences strengthen connections between sufferers and suppliers, drive affected person engagement and adherence by way of digital therapeutics, with greater than 4.4 million folks around the globe who’ve used the Glooko platform. By seamlessly integrating with digital well being information (EHRs), offering a unified machine ecosystem, and delivering actionable insights, Glooko goals to reinforce medical workflows and enhance outcomes for folks with diabetes and their care suppliers. For extra data, please go to www.glooko.com.
About Monarch Medical Applied sciences
Monarch Medical is the Charlotte, NC-based maker of the EndoTool Glucose Administration System, a number one enterprise resolution for inpatient glycemic management. Based by clinicians, Monarch’s mission is to enhance affected person security and outcomes by way of exact insulin dosing know-how. The EndoTool platform has been adopted by hospitals and well being methods throughout america to standardize and optimize insulin remedy, just about eliminating extreme hypoglycemia and lowering hyperglycemia in important care settings. For extra data, go to www.monarchmedtech.com.
1 Rushakoff RJ, Sullivan MM, MacMaster HW, et al. Affiliation between a digital glucose administration service and glycemic management in hospitalized grownup sufferers: an observational examine. Ann Intern Med 2017;166:621–627
Contacts
Media Contact
Julia Fuller
(858) 692-2001
